Conferences

To support engagement with the medical and scientific community, GSK is present at leading global conferences aligned to our four core therapy areas - Infectious Diseases, HIV, Respiratory/immunology and Oncology.

Multiple Myeloma Science Image

Oncology Medical Congresses 2024

Read more about the congresses
31 May 2024

GSK will be at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting and the 2024 European Hematology Association (EHA) Hybrid Congress.

ASCO® 2024
Date: 31 May – 4 June
Location: Chicago, Illinois, US

EHA 2024
Date: 13 – 16 June
Location: Madrid, Spain

Past conferences

2023
9-12
Dec

American Society of Hematology 2023

GSK was at the American Society of Hematology (ASH) Annual Meeting and Exposition 2023 to present its latest research advancements in blood cancers.

Read more about ASH 2023
20-24
Oct

ESMO 2023

GSK was at the European Society for Medical Oncology (ESMO) Congress 2023.

Read more about ESMO 2023
8-11
Oct

GSK was at the HLTH 2023 conference, a healthcare and innovation industry event.​

Read more about HLTH 2023
8-11
Jun

EHA 2023

GSK was at the European Hematology Association (EHA) annual meeting 2023.

Read more about EHA 2023
5-8
Jun

BIO 2023

GSK was at the BIO International Convention 2023.

Read more about BIO 2023
2-6
Jun

Oncology Medical Congress 2023

GSK was at the American Society of Clinical Oncology (ASCO) annual meeting 2023.

Read more about ASCO 2023
9-13
Sept

ERS 2023

GSK was at the European Respiratory Society International Congress (ERS) annual meeting 2023.

Read more about ERS 2023
2022
10-13
Dec

ASH 2022

GSK was at the American Society of Hematology (ASH) Annual Meeting and Exposition 2022 in New Orleans, Louisiana, USA.

Read more about ASH 2022
9-13
Sept

European Society for Medical Oncology (ESMO) Congress

At the ESMO Congress in September, we presented data that showcased our work to maximise the potential of our oncology portfolio to address unmet needs and improve patient survival. The data also shed new light on opportunities for our pipeline to deliver the next generation of cancer therapies.

Read more about ESMO 2022